Bloomberg News

Mazor Jumps to 3-Month High as FDA Approves Brain Procedures

July 16, 2012

Mazor Robotics Ltd. (MZOR) advanced to the highest level in three months after receiving approval from the U.S. Food and Drug Administration to market its Renaissance system for brain surgery procedures.

The shares gained 9.3 percent to 4.645 shekels at the close in Tel Aviv, the highest since April 11.

To contact the reporter on this story: David Wainer in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Hollywood Goes YouTube

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus